P3 Health Partners reported strong top-line results for 2023, with revenue of approximately $1.27 billion, representing 21% growth and exceeding the top end of the guidance range. The company reaffirms its 2024 outlook based on strong growth in membership, increased funding, and stabilized medical cost trends. P3 experienced higher medical expenses in December due primarily to increased hospital admissions with the combination of COVID-19 and flu exacerbations.
Total revenue was $346.9 million, an increase of 34% compared to the fourth quarter of the prior year.
Capitated revenue was $342.8 million, an increase of 35% compared to the fourth quarter of the prior year.
Net loss was $69.1 million compared to a net loss of $532.3 million in the fourth quarter of the prior year.
Adjusted EBITDA loss was $44.3 million compared to an Adjusted EBITDA loss of $40.0 million in the fourth quarter of the prior year.
P3 Health Partners anticipates reaching Adjusted EBITDA positive in 2024.